Getinge AB (publ) (GNGBY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Getinge AB (publ) (GNGBY) trades at $21.24 with AI Score 47/100 (Grade C). Getinge AB (publ) is a Swedish company providing equipment and solutions for healthcare facilities globally. Market cap: $5.78B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GNGBY: GNGBY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNGBY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNGBY: the 1 perspectives are evenly split.
How is this calculated? →Getinge AB (publ) (GNGBY) Healthcare & Pipeline Overview
Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.
What Is the Investment Thesis for GNGBY?
Getinge AB (publ) presents a notable research candidate due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 22.4 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.
Based on FMP financials and quantitative analysis
GNGBY Key Highlights
- Market capitalization of $5.78B reflects Getinge's significant presence in the medical device industry.
- Profit margin of 6.5% indicates efficient operations and profitability.
- Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
- Dividend yield of 2.43% provides an income stream for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Who Are GNGBY's Competitors?
GNGBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABT Abbott Laboratories | $95.28 | -0.13% | $165.95B | 70 |
| ALGN Align Technology, Inc. | $188.39 | +2.10% | $13.49B | 88 |
| BIO Bio-Rad Laboratories, Inc. | $295.15 | -0.57% | $7.98B | 75 |
| BRKR Bruker Corporation | $61.34 | -0.49% | $9.34B | 56 |
| CNMD CONMED Corporation | $35.57 | +5.14% | $1.07B | 73 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNGBY's Key Strengths?
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Focus on innovation
What Are GNGBY's Weaknesses?
- Exposure to currency fluctuations
- Dependence on healthcare spending
- Competition from larger medical device companies
- Potential for product recalls
What Could Drive GNGBY Stock Higher?
- Increasing demand for healthcare solutions driven by an aging global population.
- Advancements in medical technology and innovation.
- Potential strategic acquisitions to expand product portfolio and market reach.
- Expansion in emerging markets with developing healthcare infrastructure.
- Development of integrated solutions combining hardware, software, and services.
What Are the Key Risks for GNGBY?
- Currency fluctuations impacting revenue and profitability.
- Changes in healthcare regulations and reimbursement policies.
- Competition from other medical device manufacturers.
- Product recalls or safety concerns.
- Economic downturns affecting healthcare spending.
What Are the Growth Opportunities for GNGBY?
- Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
- Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
- Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
- Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
- Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.
What Opportunities Does GNGBY Have?
- Expansion in emerging markets
- Development of integrated solutions
- Strategic acquisitions
- Increasing demand for bioprocessing solutions
What Threats Does GNGBY Face?
- Changes in healthcare regulations
- Economic downturns
- Technological obsolescence
- Increased competition
What Are GNGBY's Competitive Advantages?
- Established brand reputation and long-standing relationships with customers.
- Extensive distribution network and global reach.
- Diversified product portfolio across multiple healthcare segments.
- Strong focus on innovation and research and development.
What Does GNGBY Do?
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.
What Products and Services Does GNGBY Offer?
- Provides equipment for operating rooms and intensive-care units.
- Offers sterilization solutions for healthcare facilities.
- Develops and manufactures bioprocessing systems for the life science industry.
- Provides surgical workflows solutions.
- Offers acute care therapies, including anesthesia and ventilation equipment.
- Provides sterile transfer systems and closure processing systems.
How Does GNGBY Make Money?
- Sells medical devices and equipment to hospitals, clinics, and research institutions.
- Provides service and maintenance contracts for its equipment.
- Offers software solutions for managing surgical workflows and bioprocessing operations.
- Generates revenue through a network of proprietary sales companies, agents, and distributors.
What Industry Does GNGBY Operate In?
Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.
Who Are GNGBY's Key Customers?
- Hospitals and clinics
- Research institutions
- Pharmaceutical and biotechnology companies
- Sterilization departments
How Getinge AB (publ) Is Valued
Getinge AB (publ) carries a market capitalization of $5.78B, placing it in the mid-cap category. Relative to its peer group, GNGBY's quantitative score of 47/100 is below the peer average of 72/100.
Company Profile
Getinge AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Mattias Perjos. GNGBY has traded publicly since 2012.
ROE 8%Key Financial Metrics
Return on equity for Getinge AB (publ) stands at 8.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.1%, showing how much profit it generates from its asset base. GNGBY trades at a trailing price-to-earnings ratio of 22.43, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Getinge AB (publ)'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.66 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Getinge AB (publ) revenue of about $34.93B for fiscal 2026, with EPS near $0.00. The estimate reflects 10 contributing analysts.
GNGBY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's long-term growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product launches.
- Market perception is buoyed by strong demand in the healthcare sector, particularly in surgical and intensive care solutions.
- Getinge's commitment to sustainability resonates well with socially conscious investors, enhancing its brand image.
Bear Case
- Concerns over potential supply chain disruptions could impact production timelines and delivery schedules.
- Some community members express skepticism regarding the company's ability to maintain its growth trajectory amid increasing competition.
- Recent regulatory changes in key markets may pose challenges for operational compliance and market access.
- There is a prevailing sentiment that valuation levels may be stretched, leading to potential profit-taking among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GNGBY Latest News
-
Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Yahoo! Finance: GNGBY News · May 19, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
GNGBY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNGBY.
Price Targets
Wall Street price target analysis for GNGBY.
GNGBY MoonshotScore
What does this score mean?
The MoonshotScore rates GNGBY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). Prior to joining Getinge, he held various leadership positions at other companies in the healthcare and technology sectors. His experience includes roles in sales, marketing, and general management. Perjos has a strong track record of driving growth and improving operational efficiency.
Track Record: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business, expanding its presence in key markets, and investing in innovation. He has overseen the development and launch of new products and solutions, as well as strategic acquisitions to enhance the company's competitive position. His tenure has been marked by a commitment to improving patient outcomes and delivering value to shareholders.
Getinge AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. GNGBY represents shares of Getinge AB (publ), a Swedish company. As an ADR, GNGBY allows U.S. investors to invest in Getinge without the complexities of cross-border transactions. Dividends are converted to U.S. dollars before distribution.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: GNGB
GNGBY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Higher price volatility
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established operating history
- Reputable management team
- Audited financial statements (if available)
- Positive news coverage or industry recognition
- Clear business model and value proposition
What Investors Ask About Getinge AB (publ) (GNGBY) — Healthcare
What does Getinge AB (publ) do?
Getinge AB (publ) provides a wide array of medical technology solutions, focusing on equipment and systems for operating rooms, intensive care units, and sterilization departments. The company operates through three segments: Acute Care Therapies, Life Science, and Surgical Workflows. Its products range from anesthesia machines and ventilators to bioprocessing equipment and surgical tables, serving hospitals, research institutions, and pharmaceutical companies globally. Getinge aims to improve patient outcomes and optimize healthcare processes through its innovative solutions.
What are the main risks for GNGBY?
GNGBY faces several risks, including currency fluctuations due to its global operations, which can impact revenue and profitability. Changes in healthcare regulations and reimbursement policies could also affect the demand for its products. Intense competition from other medical device manufacturers poses a threat to market share. Additionally, product recalls or safety concerns could damage the company's reputation and financial performance. Economic downturns may reduce healthcare spending, impacting Getinge's sales.
What are the key factors to evaluate for GNGBY?
Getinge AB (publ) (GNGBY) holds an AI score of 47/100 (low). P/E: 22.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does GNGBY data refresh on this page?
GNGBY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNGBY's recent stock price performance?
Getinge AB (publ) (GNGBY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNGBY overvalued or undervalued right now?
Getinge AB (publ) (GNGBY) trades at 22.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GNGBY?
Before investing in Getinge AB (publ) (GNGBY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNGBY to a portfolio?
Key strength of Getinge AB (publ) (GNGBY): Diversified product portfolio. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.